Evidence map›Paper›PMID 41003732›Full record

ArticleJournal of neurology2025

Ofatumumab treatment in patients with neuromyelitis optica spectrum disorder: a retrospective multicenter cohort study.

Xiaoxia Yang, Zhen Jia, Xuegan Lian, Rui Zhang, Bin Li, Daishi Tian, Xiuju Gao, Shougang Guo, Baojie Wang, Hongbo Liu and 12 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Xiaoxia Yang *Department of Neurology, Tianjin Medical University General Hospital, Tianjin, 300052, China.
Zhen Jia *Key Laboratory of Clinical Neurology, Ministry of Education, Hebei Medical University, Shijiazhuang, 050000, China.
Xuegan Lian *Department of Neurology, The Third Affiliated Hospital of Soochow University, Changzhou, 213003, China.
Rui ZhangDepartment of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450002, China.
Bin LiKey Laboratory of Clinical Neurology, Ministry of Education, Hebei Medical University, Shijiazhuang, 050000, China.
Daishi TianDepartment of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
Xiuju GaoDepartment of Neurology, The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, 471003, China.
Shougang GuoDepartment of Neurology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, 250021, China.
Baojie WangDepartment of Neurology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, 250021, China.
Hongbo LiuDepartment of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450002, China.
Youming LongDepartment of Neurology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510120, China.
Limei WangDepartment of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450002, China.
Jingfen ZhangDepartment of Neurology, Baotou Central Hospital, Baotou, 014042, China.
Qun XueDepartment of Neurology, The First Affiliated Hospital of Soochow University, Suzhou, 215006, China.
Zhihou LiangDepartment of Neurology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
Yongkai HanDepartment of Neurology, The Second Affiliated Hospital of Xinxiang Medical College, Xinxiang, 453002, China.
Huiyu FengDepartment of Neurology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510062, China.
Lin HuangDepartment of Neurology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 212028, China.
Pin WangDepartment of Neurology, The Second Hospital, Cheeloo College of Medicine, Shandong University, Jinan, 250013, China.
Naiyuan ShaoDepartment of Neurosurgery, The Third Affiliated Hospital of Soochow University, Changzhou, 213003, China.
Fu-Dong ShiDepartment of Neurology, Tianjin Medical University General Hospital, Tianjin, 300052, China.
Chao ZhangDepartment of Neurology, Tianjin Medical University General Hospital, Tianjin, 300052, China. chaozhang@tmu.edu.cn.ORCID http://orcid.org/0000-0002-0659-4597

Funding

Leading Talent of Changzhou "The 14th Five-Year Plan" High-Level Health Talents Training Project 2024CZLJ003National Natural Science Foundation of China 82171777National Natural Science Foundation of China 82301469Natural Science Foundation of Tianjin Municipal Science and Technology Commission 20JCJQJC00280Tianjin Health Research Project TJSQNYXXR-D2-120Tianjin Health Research Project TJWJ2024RC001Tianjin Public Health Science and Technology Major Project 24ZXGZSY00030
6 · The paper itself

Abstract

backgroundOfatumumab is a fully human anti-CD20 monoclonal antibody that selectively and highly depletes B cells. However, limited data on ofatumumab treatment are available in patients with neuromyelitis optica spectrum disorders (NMOSD). In this study, we aimed to evaluate the efficacy and safety of subcutaneous ofatumumab in patients with NMOSD.

methodsWe conducted a retrospective multicenter cohort study of patients with NMOSD who received ofatumumab treatment at 15 tertiary hospitals in China. The primary outcome was the annualized relapse rate (ARR). The secondary outcomes included disability measures (Expanded Disability Status Scale score, EDSS; the Aminoff-Logue Disability Scale, ALS), changes in aquaporin-4 IgG (AQP4-IgG) titers, and safety profiles during ofatumumab treatment.

resultsA total of 112 patients (88% female, median age 44.0 years with interquartile range [IQR 29.5-57.5]) received ofatumumab treatment for a median of 1.7 years (IQR: 1.1-2.0). The median ARR decreased significantly from 2.0 (IQR 0.7-10.0) before ofatumumab to 0 (IQR 0.0-0.0; p < 0.001) after ofatumumab. Twenty-two patients (20%) experienced 25 relapses, with 20 (80%) occurring within the first year of initiating ofatumumab treatment and 19 (76%) classified as minor. The EDSS score from start to the last follow-up also improved significantly (median: pre-treatment 3.5, IQR 2.0-6.5, post-treatment: 2.0, IQR1.0-3.5, p < 0.001). Among 94 patients, 71 (76%) showed reduced AQP4-IgG titers at last follow-up. Injection-related reactions were reported in 13 (12%) of 112 patients. Twenty-four infections occurred in 20 patients (18%) during the ofatumumab treatment, with 92% (22/24) being grade 1 or 2 (CTCAE version 5.0). Only 2 patients (2%) experienced pneumonia requiring hospitalization and recovered after antibiotic treatment (grade 3). Hypogammaglobulinemia was recorded in 14% (13/95) of patients and was not associated with infection.

conclusionsSubcutaneous ofatumumab treatment significantly reduces the relapse risk, limits worsening of disability, and reduces AQP4-IgG titers in NMOSD. Moreover, the safety profiles were generally acceptable. Further research is necessary to explore the sustained clinical response of ofatumumab in NMOSD.

Indexed as

Antibodies, MonoclonalAntibodies, Monoclonal, HumanizedNeuromyelitis OpticaAdultAquaporin 4Cohort StudiesDisability EvaluationFemaleHumansMaleMiddle AgedRetrospective StudiesTreatment OutcomeAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAquaporin 4ofatumumabEfficacyNeuromyelitis optica spectrum disorderOfatumumabSafety

Identifiers

PMID41003732

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.